Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzelmann reports on Bloomberg Television. (Source: Bloomberg)
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
